Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers

NCT00178802UNKNOWNPHASE2INTERVENTIONAL

Summary

Key Facts

Lead Sponsor

The University of Texas Health Science Center, Houston

Enrollment

24

Start Date

1996-06-01

Completion Date

2010-06-01

Study Type

INTERVENTIONAL

Official Title

Phase II Study of Mild Whole Body Hyperthermia Combined With 5-Fluorouracil/Interferon-a/Liposomal Doxorubicin in Patients With Advanced Malignancy

Interventions

thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)

Conditions

Breast NeoplasmsEndometrial NeoplasmsCervix NeoplasmsOvarian Neoplasms

Eligibility

Sex

FEMALE

Inclusion Criteria:

* Resistant breast, endometrial, cervix, or ovarian cancer
* No active metastasis to the brain
* No more than 8 previous regimes of Doxil
* Successful completion of preliminary function tests
* Good ECOG score

Exclusion Criteria:

* Active metastasis to the brain
* 8 or more previous cycles of Doxil
* Poor completion of preliminary function tests
* Poor ECOG score

Outcome Measures

Primary Outcomes

Tumor response

Time frame: 5 years

Response duration

Time frame: 5 years

Secondary Outcomes

Toxicity

Time frame: 5 years

Locations

Memorial Hermann Hospital, Houston, United States

Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers